Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Expanding the role of PARP inhibitors in breast cancer

Key clinical point: For patients with BRCA-like triple-negative breast cancer, adding veliparib to cisplatin chemotherapy may extend survival.

Major finding: All patients with BRCA-like disease had a significant improvement in progression-free survival with veliparib plus cisplatin, when compared with cisplatin alone (5.9 vs. 4.2 months; P = .006). In previously untreated patients with BRCA-like disease, those on veliparib had a significant improvement in progression-free survival (6.1 vs. 4.2 months; P = .008) and overall survival (17.8 vs. 10.3 months; P = .048).

Study details: A phase 3 trial of 335 patients with triple-negative breast cancer or BRCA-associated HER2-negative breast cancer.

Disclosures: The trial was funded by the National Institutes of Health and AbbVie. Dr. Sharma disclosed relationships with AstraZeneca, Merck, Novartis, and other companies.

Citation:

Sharma P et al. ASCO 2020, Abstract 1001.